Timothy Eugene Sullivan Sells 3,856 Shares of Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 3,856 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total transaction of $85,564.64. Following the transaction, the chief financial officer directly owned 107,080 shares of the company’s stock, valued at $2,376,105.20. The trade was a 3.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Tuesday, October 21st, Timothy Eugene Sullivan sold 10,000 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.03, for a total value of $280,300.00.

Apellis Pharmaceuticals Stock Down 2.9%

NASDAQ:APLS opened at $19.94 on Friday. Apellis Pharmaceuticals, Inc. has a 52 week low of $16.10 and a 52 week high of $31.17. The stock’s fifty day moving average is $22.89 and its two-hundred day moving average is $23.41. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of 64.32 and a beta of 0.31. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The firm had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. During the same quarter in the previous year, the business earned ($0.46) EPS. The company’s quarterly revenue was up 133.0% compared to the same quarter last year. Research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Stifel Nicolaus lowered their price objective on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 15th. The Goldman Sachs Group reissued a “sell” rating and issued a $19.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday. Wolfe Research assumed coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 6th. They issued a “peer perform” rating for the company. Finally, JPMorgan Chase & Co. cut their price objective on Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Eleven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $33.65.

Apellis Pharmaceuticals News Roundup

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterated a Buy on Apellis, signaling continued confidence in the company’s longer‑term commercial execution and pipeline upside — a supportive voice for holders focused beyond near‑term sales. Read More.
• Positive Sentiment: Stifel Nicolaus issued a Buy on APLS (or reiterated constructive coverage), adding a second favorable analyst view that could help stabilize valuation if execution improves. Read More.
• Neutral Sentiment: Analysts remain mixed on Apellis: some see upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued divergent research notes and volatile price reactions to company updates. Read More.
• Negative Sentiment: Apellis reported preliminary Q4 U.S. net product revenue of $190M and flagged weaker Syfovre sales with mixed Empaveli uptake — the main near‑term driver cited for a recent sharp weekly decline in the stock. Read More.
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) issued more pessimistic forecasts or lowered expectations, increasing downward pressure by reducing modeled revenues and price targets. Read More. Read More.
• Negative Sentiment: Significant insider selling on Jan. 13: multiple senior execs (CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others) sold shares at ~ $22.19 — filings show they still retain large stakes but the volume of disposals can be perceived negatively by the market. Read More.
• Negative Sentiment: Options flow indicated a large spike in put buying (reported >500% increase in put volume), reflecting elevated hedging and bearish positioning that can amplify short‑term volatility and downside pressure. Source: options flow reports

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Apellis Pharmaceuticals by 7.9% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 51,933 shares of the company’s stock valued at $1,305,000 after purchasing an additional 3,804 shares in the last quarter. SG Americas Securities LLC increased its holdings in Apellis Pharmaceuticals by 35.9% in the fourth quarter. SG Americas Securities LLC now owns 567,046 shares of the company’s stock valued at $14,244,000 after buying an additional 149,654 shares during the last quarter. Diversified Trust Co. purchased a new position in Apellis Pharmaceuticals in the fourth quarter valued at $476,000. Wedmont Private Capital raised its stake in Apellis Pharmaceuticals by 4.1% in the fourth quarter. Wedmont Private Capital now owns 11,883 shares of the company’s stock valued at $315,000 after buying an additional 468 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in Apellis Pharmaceuticals by 64.1% during the 3rd quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock worth $50,000 after buying an additional 857 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.